VIDEO: ASH Presidential Symposium focuses on targeting p53-mutant hematologic malignancies
Click Here to Manage Email Alerts
Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, explored clinical data on targeting p53-mutant hematologic malignancies in the presidential symposium at the ASH Annual Meeting and Exposition.
“These malignancies are particularly difficult to treat,” Davids said in a video interview with Healio. “They’re pretty universally refractory to chemotherapy-based approaches, and even some of the novel-based approaches that we’ve been developing in hematologic malignancies don’t seem to work as well in this high-risk population compared [with] other patients with the same disease.”
In his talk, Davids discussed five different modalities to try to target p53-mutant hematologic malignancies.
“Hopefully this will be a new step forward into getting better outcomes for these patients,” Davids said.
Collapse
Davids, MS. Presidential Symposium: Therapy of p53 Mutant Hematologic Malignancies. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts